European Journal of Cancer
Volume 36, Issue 16 , Pages 2083-2089 , October 2000

BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer

  • D Turchetti

      Affiliations

    • Università di Modena e Reggio Emilia, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, Oncologia ed Ematologia, Via del Pozzo 71, 41100 Modena, Italy
    • ,
  • L Cortesi

      Affiliations

    • Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, Via Campi 287, 41100 Modena, Italy
    • ,
  • M Federico

      Affiliations

    • Università di Modena e Reggio Emilia, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, Oncologia ed Ematologia, Via del Pozzo 71, 41100 Modena, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-059-422577; fax: +39-059-424549
    • ,
  • C Bertoni

      Affiliations

    • Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, Via Campi 287, 41100 Modena, Italy
    • ,
  • L Mangone

      Affiliations

    • Università di Modena e Reggio Emilia, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, Oncologia ed Ematologia, Via del Pozzo 71, 41100 Modena, Italy
    • ,
  • Se Ferrari

      Affiliations

    • Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, Via Campi 287, 41100 Modena, Italy
    • ,
  • V Silingardi

      Affiliations

    • Università di Modena e Reggio Emilia, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Sezione di Medicina Interna, Oncologia ed Ematologia, Via del Pozzo 71, 41100 Modena, Italy

Received 6 March 2000 ,Revised 12 June 2000 ,Accepted 21 July 2000.

References 

  1. Federico M, Mangone L, Silingardi V, Lauriola P. Cancer incidence in the Province of Modena. In: Zanetti, Crosignani, Rossi, Vigan, eds. Cancer in Italy, Vol. 2. Rome, Il Pensiero Scientifico Editore, 1997, 244–247.
  2. Knudson AG. Mutation and cancer (statistical study of retinoblastoma). Proc. Natl. Acad. Sci. USA. 1971;68:820–823
  3. Haber DA, Housman DE. Rate-limiting steps (the genetics of pediatric cancers). Cell. 1991;64:5–8
  4. Cannon-Albright LA, Skolnick LH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N. Engl. J. Med. 1988;319:533–537
  5. Sattin RW, Rubin GL, Webster LA, et al.  Family history and risk of breast cancer. J. Am. Med. Assoc. 1985;253:1908–1913
  6. Schwartz AG, King MC, Belle SH, Satariano WA, Swanson GM. Risk of breast cancer to relatives of young breast cancer patients. J. Natl. Cancer Inst. 1985;75:665–668
  7. Anderson DE. Genetic study of breast cancer (identification of high risk group). Cancer. 1974;34:1090–1097
  8. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am. J. Epidemiol. 1990;131:961–972
  9. Miki Y, Swensen J, Shattuck-Eidens D, et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  10. Wooster R, Neuhausen S, Mangion J, et al.  Localization of a breast susceptibility gene, BRCA2, to chromosome 13q 12-13. Science. 1994;265:2088–2090
  11. Fitzgerald MG, MacDonald DJ, Krainer M, et al.  Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N. Engl. J. Med. 1996;334:137–142
  12. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N. Engl. J. Med. 1996;334:137–142
  13. Ithier G, Girard M, Stoppa-Lyonnet D. Breast cancer and BRCA1 mutations. N. Engl. J. Med. 1996;334:1198–1199
  14. Couch FJ, De Shano ML, Blackwood A, et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 1997;336:1409–1415
  15. Malone KE, Daling JR, Thompson JD, et al.  BRCA1 mutations and breast cancer in the general population (analyses in women before age 35 years and in women before age 45 years with first-degree family history). J. Am. Med. Assoc. 1998;279:922–929
  16. Peto J, Collins N, Barfoot R, et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 1999;91:943–949
  17. Krainer M, Silva-Arrieta S, Fitzgerald MG, et al.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N. Engl. J. Med. 1997;336:1416–1421
  18. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Breast carcinoma in women of 35 years of age or younger. Ann. Surg. 1984;9:191–199
  19. Sigurdsson H, Baldetorp B, Borg A, et al.  Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med. 1990;322:1045–1053
  20. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome (are there age-differentials?). J. Natl. Cancer Inst. Monogr. 1994;16:37–42
  21. Marcus JN, Watson P, Page DL, et al.  Hereditary breast cancer. Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77:697–709
  22. Breast Cancer Linkage Consortium . Pathology of familial breast cancer (differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases). Lancet. 1997;349:1505–1510
  23. Armes JE, Egan AJM, Southey MC, et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. Cancer. 1998;83:2335–2345
  24. Robson M, Gilewski T, Haas B, et al.  BRCA-associated breast cancer in young women. J. Clin. Oncol. 1998;16:1642–1649
  25. Cortesi L, Turchetti D, Bertoni C, et al.  Comparison between genotype and phenotype identifies a high risk population carrying BRCA1 mutations. Genes Chrom. Cancer. 2000;27:130–135
  26. Porter DE, Cohen BB, Wallace MR, et al.  Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br. J. Surg. 1994;81:1512–1515
  27. Verhoog LC, Brekelmans CT, Seynaeve C, et al.  Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316–321
  28. Lee JS, Wacholder S, Struewing JP, et al.  Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999;91:259–263
  29. Federico M, Maiorana A, Mangone L, et al.  Identification of families with Hereditary Breast Cancer for clinico-mammographic surveillance. The Modena Study Group Proposal. Breast Cancer Res. Treat. 1999;55:213–221
  30. Friedman LS, Ostermeyer EA, Szabo CI, et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet. 1994;8:399–404
  31. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 1983;166:557–580
  32. Struewing JP, Hartge P, Wacholder S, et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 1997;336:1401–1408
  33. Fodor FH, Wenston A, Bleiweiss IJ, et al.  Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet. 1998;63:45–51
  34. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Gen. 1995;57:1457–1462

PII: S0959-8049(00)00287-2

European Journal of Cancer
Volume 36, Issue 16 , Pages 2083-2089 , October 2000

Article Tools